Prognostic Value of Pathological Response After Conversion Therapy and Salvage Surgery in Unresectable Hepatocellular Carcinoma
Liver International · 2026
DOI: 10.1111/liv.70681 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Liver International, 2026. Verfasst von Qi-Yu Chi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Salvage Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fujian Provincial Health Technology Project, The Natural Science Foundation of Fujian Province.
Abstract (Originalsprache)
Background and Aims To evaluate the prognostic significance of pathological response in patients with initially unresectable hepatocellular carcinoma (uHCC) who underwent salvage resection after successful conversion with lenvatinib, anti‐PD‐1 antibodies, and locoregional therapy (LPLRT).
Methods
This multicenter retrospective study included 102 uHCC patients who achieved curative resection after LPLRT across four tertiary centers in China. Residual viable tumour (pRVT) ratio was used to assess pathological response. Optimal pRVT cutoffs for overall survival (OS) and recurrence‐free survival (RFS) were identified using X‐tile (a statistical tool that identifies optimal prognostic cutoff values for continuous variables by systematically maximizing the log‐rank statistic). Survival was analysed by Kaplan–Meier and log‐rank tests, and prognostic factors by Cox regression analyses.
Results
Among 102 patients, 25 (24.5%) achieved pathological complete response (pCR). X‐tile identified pRVT thresholds of 10% and 35% as optimal for predicting OS and RFS, respectively. Patients with pRVT ≤ 10% had superior OS (1‐, 2‐, 3 year: 96.6%, 89.8%, 82.5%) compared with pRVT > 10% (95.5%, 73.0%, 49.4%; p = 0.002). pRVT ≤ 35% was associated with longer RFS (1‐, 2 year: 60.5%, 47.1% vs. 24.0%, 10.0%; p < 0.001). Similar trends persisted after excluding pCR cases. On multivariate analysis, NLR < 2.6, adjuvant therapy, and pRVT ≤ 10% independently predicted improved OS, while age < 60 years was adverse for RFS, and NLR < 2.6 and pRVT ≤ 35% were independently associated with prolonged RFS. No clinical variables predicted pRVT thresholds. Conclusions pRVT refines postoperative prognostic assessment in uHCC after multimodal conversion therapy. Thresholds of ≤ 10% for OS and ≤ 35% for RFS serve as practical cutoffs for postoperative risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
- Institute of Abdominal Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
- Clinical Research Center for Hepatobiliary Pancreatic and Gastrointestinal Malignant Tumors Precise Treatment of Fujian Province, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
- Fujian Provincial Key Laboratory of Precision Medicine for Cancer, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
- Department of Hepatopancreatobiliary Surgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
- Department of Pathology, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Förderung
- Fujian Provincial Health Technology Project
- The Natural Science Foundation of Fujian Province
Zitieren
APA
Chi, Q. Y., Gao, X. D., Wang, M., Liu, Q. Y., Zeng, Y. Y., Yang, L. F., Liu, Z. J., Wang, S. J., Weng, S. G., & Zhang, Z. B. (2026). Prognostic Value of Pathological Response After Conversion Therapy and Salvage Surgery in Unresectable Hepatocellular Carcinoma. Liver International. https://doi.org/10.1111/liv.70681
Vancouver
Chi QY, Gao XD, Wang M, Liu QY, Zeng YY, Yang LF, et al. Prognostic Value of Pathological Response After Conversion Therapy and Salvage Surgery in Unresectable Hepatocellular Carcinoma. Liver International. 2026. doi:10.1111/liv.70681
BibTeX
@article{Chi2026,
author = {Chi, Qi-Yu and Gao, Xiao-Di and Wang, Mi and Liu, Quan-Yuan and Zeng, Yong-Yi and Yang, Lan-Fang and Liu, Zi-Jian and Wang, Shuang-Jia and Weng, Shan-Geng and Zhang, Zhi-Bo},
title = {Prognostic Value of Pathological Response After Conversion Therapy and Salvage Surgery in Unresectable Hepatocellular Carcinoma},
journal = {Liver International},
year = {2026},
doi = {10.1111/liv.70681}
}
EUVIMED